INS and Hypoglycemia: IGF-2 exerts insulin-like bioactivity that directly induces hypoglycemia, while simultaneously suppressing endogenous insulin and C-peptide secretion—exactly matching the patient’s biochemical profile (low C-peptide and hypoglycemia) (12–14).